Published 19:58 IST, January 19th 2021

Russia's second COVID-19 vaccine EpiVacCorona '100% effective' in early trials: Report

Russia’s 2nd COVID vaccine candidate, EpiVacCorona, has proved to be 100% effective in early-stage trials, consumer health watchdog Rospotrebnadzor reported.

Reported by: Bhavya Sukheja
Follow: Google News Icon
  • share
null | Image: self
Advertisement

Russia’s second coronavirus vaccine candidate, EpiVacCorona, has proved to be 100 per cent effective in early-stage trials, consumer health watchdog Rospotrebnzor told TASS news agency. According to Russian local media outlet, data based on Phase I and II trials were released before start of Phase III trial. However, Rospotrebnzor reported that that effectiveness of vaccine is me up of its immunological effectiveness and preventative effectiveness and results of initial two trials have shown “immunological effectiveness of EpiVacCorona vaccine to be 100%”. 

According to TASS media outlet, phase I and II studies tested safety, side effects and immunogenicity of potential vaccine in 100 people aged 18-60. It is worth noting that Russia h begun testing of EpiVacCorona, which is being developed by Siberia’s vector Institute, in November. 

Advertisement

RE: Kremlin Dismisses Calls To Release Alexei Navalny, Says It Is Russia's 'internal Affair'

RE: US: Woman Who Stole Nancy Pelosi's Laptop 'planned To Sell It To Russia'

Advertisement

Russia’s mass vaccination 

Meanwhile, Russia has alrey approved Sputnik V vaccine, which Moscow says has shown 92 per cent effectiveness at protecting people from dely disease. So far, country has also inoculated nearly 60 per cent of its population against COVID-19. Last week, President Vlimir Putin also ordered mass vaccination to start this week. 

Russia has deployed 277,000 COVID beds in hospitals. mass vaccination campaign continues in country with aim of vaccinating every citizen. Earlier, Putin h said that Sputnik V has at least 95 per cent efficacy, ding that Russia has given world good, safe, and efficient vaccine products. Russian President thanked Gamaleya Research Institute of Epidemiology and Microbiology, Russian Direct Investment Fund (RDIF) for producing vaccine against novel coronavirus. Russian leer cited health experts, saying that shot hits 96-97 per cent efficacy in one dose as it is ministered into patient’s body. According to Kremlin spokesperson Dmitry Peskov, Putin will receive Sputnik V COVID-19 vaccine soon.

Advertisement

RE: Russia's 'makeshift' Court Orders Kremlin Critic Navalny's Custody Until Mid-Feb

RE: Russia Not Satisfied With Germany's Reply On Investigation Into Navalny's Poisoning

Advertisement

19:58 IST, January 19th 2021